Is 1mg Wegovy Enough to Cause Weight Loss?

What is the 1mg dose supposed to achieve?

Wegovy (semaglutide) is a GLP-1 receptor agonist made by Novo Nordisk. It works by mimicking a gut hormone that signals fullness to your brain, slows the rate at which food leaves your stomach, and dampens appetite. All of that is happening at 1mg, it is an active, pharmacological dose. What the 1mg level is not, in the licensed titration plan, is the endpoint.

The standard schedule moves from 0.25mg at weeks one to four, through 0.5mg and 1mg in roughly four-week steps, and then onward to 1.7mg and the 2.4mg maintenance dose. Some people notice a real reduction in hunger and start losing weight at the 1mg stage of the titration. Others feel modest changes and find the bigger shift comes once they reach 1.7mg or 2.4mg. Both experiences are normal, the biology of appetite is individual.

A common misconception is that staying at a lower dose is automatically the safer or gentler choice. In fact, staying too long at a sub-therapeutic dose may simply mean you're tolerating the medicine without getting its full benefit. The titration schedule exists to balance tolerability with effectiveness, not to delay progress for its own sake. You can read more about how Wegovy's dose steps are structured if the full picture would help.

Does the evidence suggest 1mg produces meaningful weight loss?

The headline clinical trial data for Wegovy (around 15% average body-weight reduction over 68 weeks) was measured at the 2.4mg maintenance dose in the STEP 1 trial, published in the New England Journal of Medicine. The trial was not designed to isolate the effect of 1mg on its own, so there is no neat published figure saying "at 1mg, average loss is X%". What researchers observed across the programme was a dose-response pattern: more weight loss at higher doses. That is consistent with the pharmacology.

So yes, 1mg does something. But the evidence base behind Wegovy's approval (and why NICE recommended it (TA875)) rests on the 2.4mg data. If your prescriber is titrating you toward that level, the 1mg phase is doing its job: keeping you in treatment while your system adjusts.

For context on a related question, it is worth looking at whether the 0.5mg semaglutide dose is enough, which explores the earlier step in the same progression.

When might someone stay at 1mg rather than move up?

Not everyone follows a textbook schedule. Some people experience side effects (nausea, loose stools, fatigue) that make their prescriber cautious about moving up quickly. Staying at 1mg longer than the standard four weeks can be a reasonable clinical decision while your body settles. It is not a sign of failure.

There are also situations where a prescriber might decide that 1mg is enough for now: if weight loss is progressing steadily, if tolerance is still patchy, or if other health factors warrant a slower approach. This is precisely why every dose decision at a service like ours at nume involves a clinical review, not an automated process. A real prescriber looks at how you're getting on before authorising the next step.

If you're wondering about the practical difference between consecutive doses, the move from 1mg to 1.7mg is worth reading about, it covers what typically changes when the dose increases.

Is there a point at which 1mg is clearly not working?

NICE's guidance on semaglutide notes that treatment should be reviewed if a patient has not achieved at least 5% weight loss after six months at the maintenance dose. At 1mg, you are not yet at that maintenance dose, so applying the six-month yardstick to the 1mg phase misreads what the phase is for.

That said, if you have been at 1mg for considerably longer than the planned four weeks and have not noticed any reduction in appetite or any weight change at all, that is worth raising with your prescriber. It may point to a need to move up, or occasionally to a question about whether semaglutide is the right medicine for you. If Wegovy has eventually stopped producing results even at 2.4mg, that is a separate situation covered in detail elsewhere.

For information on what to expect from the pen itself at this dose, the 1mg Wegovy pen page has practical detail. And if you are still at the research stage, our Wegovy overview covers the full picture of how treatment works. Private treatment starts with a free consultation, you can check your eligibility when you're ready, and a GPhC-registered prescriber will review your situation the same day.